Palvella Therapeutics to Present at Chardan Healthcare Conference…

Event summary

Palvella Therapeutics will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026, at 1:45 p.m. ET.
The event will be webcast live and archived for 90 days on Palvella's website.
Palvella focuses on developing therapies for rare skin diseases and vascular anomalies with no FDA-approved treatments.
Lead product candidate QTORIN™ 3.9% rapamycin anhydrous gel is in development for microcystic lymphatic malformations and other conditions.
Second product candidate QTORIN™ pitavastatin is being developed for disseminated superficial actinic porokeratosis.

The big picture

Palvella Therapeutics' participation in the Chardan Healthcare Conference underscores its focus on rare disease therapies, an area with significant unmet medical needs. The company's development pipeline, particularly its lead candidate QTORIN™ rapamycin, positions it in a niche market with potential for orphan drug exclusivity. The strategic context involves navigating regulatory pathways for novel therapies in underserved patient populations.

What we're watching

Regulatory Progress: Whether Palvella can secure FDA approval for QTORIN™ rapamycin and pitavastatin, given the lack of current treatments for these rare conditions.
Clinical Development: The pace at which Palvella advances its clinical trials and meets anticipated development milestones.
Financial Runway: How Palvella's financial resources and expected runway will support its ongoing and planned clinical trials.